

Drug Utilization Review (DUR) Meeting Minutes September 3, 2014

Members Present: John Savageau, Jeffrey Hostetter, Peter Woodrow, Russ Sobotta, Tanya Schmidt, Steve Irsfeld, Michael Booth, Carlotta McCleary, Laura Schield, Katie Kram, Wendy Brown, Emmet Kenney

Members Absent: Todd Twogood, James Carlson, Leann Ness

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

J. Savageau called the meeting to order at 1:00 p.m. Chair J. Savageau asked for a motion to approve the minutes from the June meeting. M. Booth moved that the minutes be approved, and P. Woodrow seconded the motion. Chair J. Savageau called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget update

B. Joyce distributed and discussed a table showing drug rebate amounts from 1st quarter 2010 through 4th quarter 2013. Approximately 8-9 million dollars are paid out to pharmacies each quarter. Approximately 4-4.5 million dollars are recouped from drug rebates.

Northera second review

A motion and second were made at the June meeting to place Northera on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Oral allergen extracts second review

A motion and second were made at the June meeting to place oral allergen extracts on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Updated AAP guidelines for palivizumab prophylaxis

B. Joyce discussed the updated guidelines for palivizumab (Synagis). The updated guidelines were incorporated into a prior authorization form for the board to review. L. Willshaw, representing MedImmune, spoke regarding Synagis. A motion was made by K. Kram to accept the changes to the current Synagis form to reflect the updated AAP guidelines. W. Brown seconded the motion. Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent. The board asked that data be brought back to the December meeting showing how many children during the 2013-2014 Synagis season would not have received medication based on the new guidelines. The board also asked for RSV hospitalization information from the 2013-2014 season, if available. B. Joyce stated that hospitalization data would be virtually impossible to obtain because the diagnosis is not always used for billing purposes.

NDQuits protocol update

B. Joyce informed the board of changes in how the recipients receive the form with the updated protocol. Currently, ND Medicaid members who wish to use tobacco cessation medications are required to enroll in phone counseling provided by NDQuits. The new proposed process will allow coverage for medications when participating in face to face or group counseling, which will encourage more successful quit attempts.

Hepatitis C treatment and compliance

B. Joyce reviewed current treatment guidelines as well as utilization data for Sovaldi and Olysio. Board members reviewed prior authorization forms for Sovaldi and Olysio. The department would like guidance from the board on criteria for approval as well as long-term oversight to ensure compliance. The board made a recommendation that to demonstrate drug and alcohol free for the past 12 months that all PA requests would be accompanied by 12 months of urine screens.

Benzodiazepine review

B. Joyce reviewed benzodiazepine utilization with the board. Data regarding duplicate therapy of benzodiazepines was also discussed. The board asked that more information be provided at the December meeting including ages of recipients, prescribers, and diagnoses.

Transdermal androgen review

B. Joyce reviewed transdermal androgen information with the board. Mike Gonzales, representing Abbvie, spoke regarding Androgel. P. Woodrow made a motion to place transdermal androgens on prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Phosphate binders review

B. Joyce reviewed phosphate binder information with the board. There was no public comment. M. Booth made a motion to place Velphoro on prior authorization. P. Woodrow seconded the motion. This topic will be reviewed at the next meeting.

Zontivity Review

B. Joyce reviewed Zontivity information with the board. There was no public comment. W. Brown made a motion to place Zontivity on prior authorization. P. Woodrow seconded the motion. This topic will be reviewed at the next meeting.

Evzio Review

B. Joyce reviewed Evzio information with the board. There was no public comment. J. Hostetter made a motion to place Evzio on prior authorization. L. Schield seconded the motion. This topic will be reviewed at the next meeting.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. P. Woodrow moved to approve the new criteria and M. Booth seconded the motion. Chair J. Savageau called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held December 3, in Bismarck. J. Hostetter made a motion to adjourn the meeting. P. Woodrow seconded. The motion passed with no audible dissent. J. Savageau adjourned the meeting.